Seeking to Bring New Options to
Patients with Blood Cancers

Seeking to Bring New Options to Patients with Blood Cancers

ABOUT US

We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers.

PACRITINIB

CTI is evaluating pacritinib in the Phase 3 PACIFICA trial for patients with myelofibrosis and severe thrombocytopenia.

INVESTORS

For the latest corporate updates and press releases please visit the investor section of our website.

PATIENTS

We are actively recruiting individuals with myelofibrosis to participate in clinical trials.

Recent News

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

SEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at… Read More

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

SEATTLE, Aug. 24, 2021 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including… Read More

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

SEATTLE, June 1, 2021 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients… Read More

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

SEATTLE, March 31, 2021  — CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”) seeking approval of pacritinib as a treatment for myelofibrosis patients… Read More